GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

Adolescent Alemtuzumab / therapeutic use Bone Marrow Cells / cytology Child Child, Preschool Disease-Free Survival Female Fetal Blood / cytology Graft vs Host Disease / etiology Hematopoietic Stem Cell Transplantation / adverse effects Humans Leukemia, Myeloid, Acute / mortality Male Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality Proportional Hazards Models Recurrence Survival Rate Thyroglobulin / therapeutic use Transplantation Conditioning Whole-Body Irradiation

Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
14 05 2019
Historique:
received: 19 12 2018
accepted: 07 03 2019
entrez: 5 5 2019
pubmed: 6 5 2019
medline: 12 5 2020
Statut: ppublish

Résumé

We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival (CRFS) among pediatric patients with acute leukemia (n = 1613) who underwent transplantation with 1 antigen-mismatched (7/8) bone marrow (BM; n = 172) or umbilical cord blood (UCB; n = 1441). Multivariate analysis was performed using Cox proportional hazards models. To account for multiple testing,

Identifiants

DOI: 10.1182/bloodadvances.2018030171 PMID: 31053571 PMC: PMC6517657
pubmed: 31053571
pii: bloodadvances.2018030171
doi: 10.1182/bloodadvances.2018030171
pmc: PMC6517657
doi:

Substances chimiques

Alemtuzumab 3A189DH42V
Thyroglobulin 9010-34-8

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1441-1449

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States

Références

Bone Marrow Transplant. 2000 May;25(9):943-8
pubmed: 10800061
Blood. 2016 May 19;127(20):2427-38
pubmed: 26884374
Bone Marrow Transplant. 2016 Aug;51(8):1113-20
pubmed: 27042847
Blood. 2012 Jun 21;119(25):6155-61
pubmed: 22573402
Pediatr Hematol Oncol. 2014 Nov;31(8):754-64
pubmed: 25325678
Bone Marrow Transplant. 2001 Apr;27(8):777-83
pubmed: 11477433
Blood Cells Mol Dis. 2004 Nov-Dec;33(3):281-7
pubmed: 15528145
Blood. 2017 Aug 3;130(5):677-685
pubmed: 28588018
Biol Blood Marrow Transplant. 2017 Oct;23(10):1714-1721
pubmed: 28684372
Biol Blood Marrow Transplant. 2007 May;13(5):584-93
pubmed: 17448918
Biol Blood Marrow Transplant. 2015 Mar;21(3):473-82
pubmed: 25485863
Haematologica. 2016 Jun;101(6):764-72
pubmed: 27036159
Biol Blood Marrow Transplant. 2016 Mar;22(3):499-504
pubmed: 26612281
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Br J Haematol. 2014 Jun;165(5):688-98
pubmed: 24588540
Bone Marrow Transplant. 2002 Sep;30(6):359-66
pubmed: 12235520
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Biol Blood Marrow Transplant. 2015 Apr;21(4):707-12
pubmed: 25598277
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16
pubmed: 26211985
Biol Blood Marrow Transplant. 2012 Aug;18(8):1204-10
pubmed: 22406037
Bone Marrow Transplant. 2005 Dec;36(11):1001-8
pubmed: 16184180
J Clin Oncol. 2004 Dec 15;22(24):4872-80
pubmed: 15520055
Blood. 2010 Apr 29;115(17):3437-46
pubmed: 20040760
Blood. 2011 Jul 14;118(2):223-30
pubmed: 21613256
Bone Marrow Transplant. 2012 Nov;47(11):1385-90
pubmed: 22056642
Blood. 2015 Feb 19;125(8):1333-8
pubmed: 25593335
Br J Haematol. 2006 Jul;134(2):196-201
pubmed: 16846478
Blood. 2002 Jul 15;100(2):406-14
pubmed: 12091329
Blood. 2017 Oct 12;130(15):1699-1705
pubmed: 28724539
N Engl J Med. 2014 Jul 24;371(4):339-48
pubmed: 25054717
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Blood. 2016 Jun 30;127(26):3450-7
pubmed: 27099151
Br J Haematol. 2012 Mar;156(5):656-66
pubmed: 22224700
Blood. 2010 Mar 4;115(9):1843-9
pubmed: 20029048
Lancet. 2007 Jun 9;369(9577):1947-54
pubmed: 17560447
Curr Opin Immunol. 2006 Oct;18(5):565-70
pubmed: 16893632
N Engl J Med. 2014 Oct 30;371(18):1685-94
pubmed: 25354103
Blood. 2014 Jan 2;123(1):126-32
pubmed: 24184682

Auteurs

Rohtesh S Mehta (RS)

Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.

Shernan G Holtan (SG)

University of Minnesota, Minneapolis, MN.

Tao Wang (T)

Center for International Blood and Marrow Transplant Research and.
Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.

Michael T Hemmer (MT)

Center for International Blood and Marrow Transplant Research and.

Stephen R Spellman (SR)

Be the Match/National Marrow Donor Program, Center for International Blood and Marrow Transplant Research, Minneapolis, MN.

Mukta Arora (M)

Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN.

Daniel R Couriel (DR)

Utah Blood and Marrow Transplant Program, Salt Lake City, UT.

Amin M Alousi (AM)

Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.

Joseph Pidala (J)

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL.

Hisham Abdel-Azim (H)

Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA.

Ibrahim Ahmed (I)

Department of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, MO.
ORCID: 0000-0001-5525-9798

Mahmoud Aljurf (M)

Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Medhat Askar (M)

Baylor University Medical Center, Dallas, TX.

Jeffery J Auletta (JJ)

Division of Hematology/Oncology/Bone Marrow Transplantation and.
Division of Infectious Diseases, Blood and Marrow Transplant Program and Host Defense Program, Nationwide Children's Hospital, Columbus, OH.

Vijaya Bhatt (V)

Nebraska Medical Center, Omaha, NE.
ORCID: 0000-0003-2513-0533

Christopher Bredeson (C)

The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Saurabh Chhabra (S)

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.

Shahinaz Gadalla (S)

Division of Cancer Epidemiology and Genetics, National Cancer Institute Clinical Genetics Branch, National Institutes of Health, Rockville, MD.
ORCID: 0000-0002-3255-8143

James Gajewski (J)

Oregon Health and Science University, Portland, OR.

Robert Peter Gale (RP)

Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.

Usama Gergis (U)

Hematologic Malignancies and Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY.

Peiman Hematti (P)

Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI.

Gerhard C Hildebrandt (GC)

Markey Cancer Center, University of Kentucky, Lexington, KY.

Yoshihiro Inamoto (Y)

Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Carrie Kitko (C)

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.

Pooja Khandelwal (P)

Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Margaret L MacMillan (ML)

University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN.

Navneet Majhail (N)

Blood and Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

David I Marks (DI)

Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.

Parinda Mehta (P)

Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Taiga Nishihori (T)

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL.
ORCID: 0000-0002-2621-7924

Richard F Olsson (RF)

Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0001-5970-2128

Attaphol Pawarode (A)

Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI.

Miguel Angel Diaz (MA)

Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.

Tim Prestidge (T)

Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.

Muna Qayed (M)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.

Hemalatha Rangarajan (H)

Nationwide Children's Hospital, Columbus, OH.

Olle Ringden (O)

Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Ayman Saad (A)

Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
ORCID: 0000-0003-0003-0130

Bipin N Savani (BN)

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
ORCID: 0000-0002-3304-9965

Sachiko Seo (S)

Department of Hematology and Oncology, National Cancer Research Center East, Chiba, Japan.

Ami Shah (A)

Division of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford School of Medicine, Palo Alto, CA.

Niketa Shah (N)

Yale New Haven Hospital, New Haven, CT.

Kirk R Schultz (KR)

Department of Pediatric Hematology, Oncology, and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, BC, Canada.

Melhem Solh (M)

The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA.

Thomas Spitzer (T)

Massachusetts General Hospital, Boston, MA.

Jeffrey Szer (J)

Department of Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Parkville, VIC, Australia.
ORCID: 0000-0001-6783-2301

Takanori Teshima (T)

Kyushu University Hospital, Sapporo, Japan.

Leo F Verdonck (LF)

Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands.

Kirsten M Williams (KM)

Children's Research Institute, Children's National Health Systems, Washington, DC.

Baldeep Wirk (B)

Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA.

John Wagner (J)

Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA; and.

Jean A Yared (JA)

Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD.

Daniel J Weisdorf (DJ)

University of Minnesota, Minneapolis, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Alemtuzumab › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système hématopoïétique › Cellules de la moelle osseuse › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Enfant d'âge préscolaire › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Structures de l'embryon › Foetus › Sang foetal › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie-lymphome lymphoblastique à précurseurs B et T › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Modèles des risques proportionnels › GRFS and CRFS in alternative donor...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Iodoprotéines › Thyroglobuline › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Conditionnement pour greffe › GRFS and CRFS in alternative donor...
questionsmedicales.fr › Techniques d'investigation › Irradiation corporelle totale › GRFS and CRFS in alternative donor...